The Latest Breaking News from Vaxcyte

Vaxcyte's 31-Strain Pneumococcal Vaccine Met Its Main Antibody Goals Against Prevnar 20 and Capvaxive in Phase 3 Trial

Vaxcyte's VAX-31 met its main Phase 3 antibody goals vs. Prevnar 20 and Capvaxive in adults 50+, but the data are topline and approval is years away.

Medical Daily · 18h ago

Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

Barchart · Mar 2

Sugar starts corroding your teeth within seconds – here’s how to protect your pearly whites from decay

Between Halloween candy, Thanksgiving pies and holiday cookies, the end of the year is often packed with opportunities to consume sugar. But what happens in your mouth during those first minutes and hours after eating those sweets?

The Conversation · Dec 2, 2025

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

Benzinga · Aug 4, 2022